Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AZ to take $100m hit from ending trial of CV drug Epanova

pharmaceutical-technologyJanuary 15, 2020

Tag: AZ , CV , Epanova , AstraZeneca

PharmaSources Customer Service